Lipoma, atypical lipomatous tumour and liposarcoma

Fatty lumps are among the commonest reasons people are referred to a tumour clinic, and the overwhelming majority turn out to be harmless. But “fatty lump” covers a family of tumours that runs from completely benign to genuinely dangerous, and the words used for them (lipoma, atypical lipomatous tumour, liposarcoma) are confusingly similar.

This page sets the family out as a ladder, from harmless to serious, and answers the practical questions at each rung: how the diagnosis is made, when surgery is needed, and what follow-up looks like afterwards.

The essentials

1. A lipoma is harmless and does not turn into cancer. Once the diagnosis is secure, most need no treatment at all.
2. Four features mean a fatty lump should be imaged before it is removed: it is large, it is deep rather than just under the skin, it is growing, or it has appeared in later adult life.
3. Diagnose before removing. A suspicious fatty lump shelled out without imaging and a properly tested biopsy is the single commonest route to trouble here: it roughly triples the chance of the tumour coming back.
4. The liposarcomas are not one disease, and their treatment differs substantially. The exact name, confirmed by genetic testing on the biopsy, is what makes the right plan possible.
5. If you have had an atypical lipomatous tumour removed, follow-up lasts years. Recurrence is often late, and report any new lump or pain in the area rather than waiting for your next appointment.

The family at a glance

How they actually fit together

The names suggest one disease at increasing strength. The biology says otherwise, and understanding this dissolves most of the confusion.

One family is a genuine spectrum. Atypical lipomatous tumour, well-differentiated liposarcoma and dedifferentiated liposarcoma all share the same gene abnormality: extra copies of MDM2. They are one disease at different stages: the low-grade form, and what it can become. This family occurs mostly in older adults, and it is the reason this page talks so much about follow-up.

Myxoid liposarcoma is not part of that spectrum. It carries a completely different genetic change (a fusion of two genes, found in about 96% of cases when tested), occurs in noticeably younger people, and behaves by its own rules. It did not start life as a lipoma or an ALT, and no amount of watching a lipoma will catch one.

Pleomorphic liposarcoma stands alone. It is the rarest of the group (fewer than 15% of liposarcomas), has no single genetic signature, and behaves like any high-grade sarcoma.

And the reassurance that follows from the biology: a lipoma does not turn into any of these. The only transformation that genuinely happens in this family is an ALT becoming dedifferentiated, which is precisely why ALTs are followed up and lipomas are not.

Lipoma: the harmless one

A lipoma is a soft, painless lump of normal fat cells, usually just under the skin. It is benign in the full sense of the word: it does not spread, and it does not turn into cancer.

A lipoma that has been confidently diagnosed does not need to be removed. Surgery is reasonable when the lump is uncomfortable, keeps growing, or bothers the person who owns it, and necessary when the diagnosis is not actually secure, which is the real point of this page.

When a fatty lump deserves a closer look

The features that separate “reassure and leave” from “image and biopsy” are simple:

• Size. Bigger lumps are more suspicious. In a series of 336 patients with fat tumours at a sarcoma centre, the atypical tumours were on average 15 cm across; the lipomas averaged 7 cm.
• Depth. A lump beneath the muscle layer is treated with more suspicion than one just under the skin: deep lesions were significantly more likely to be atypical.
• Growth. A fatty lump that is clearly enlarging has forfeited the benefit of the doubt.
• Age. The atypical tumours occurred in older patients.

None of these features makes a lump a sarcoma; most large, deep fatty lumps are still benign. They are simply the triggers for doing the diagnosis properly: an MRI, and usually a needle biopsy, before anything is removed. A suspicious fatty lump shelled out at a minor operation without that work-up is the classic route to trouble, for reasons the next section makes clear.

Atypical lipomatous tumour: the in-between one

An atypical lipomatous tumour (ALT) sits between lipoma and sarcoma. It grows slowly and does not spread to other parts of the body, but left alone it keeps growing, and if removed casually it tends to come back.

One naming point saves a lot of alarm: ALT and “well-differentiated liposarcoma” are the same tumour. By convention the limb version is called ALT and the abdominal version is called well-differentiated liposarcoma: the same disease, at sites where it is harder to remove completely. Patients who read both names about themselves have not been given two diagnoses.

Why the genetic test matters

Down the microscope, an ALT can be almost indistinguishable from a lipoma: in the series above, a quarter of biopsies from proven ALTs looked entirely benign. The reliable separator is a genetic feature: ALTs carry extra copies of a gene called MDM2, and lipomas do not. Testing the biopsy for MDM2 settles the question.

This is not an academic nicety. In that same series, patients whose tumour was biopsied and MDM2-tested before surgery had a recurrence rate of 16%; those operated on without it recurred at 57%. Knowing what the lump is changes how the operation is done (the whole tumour taken out with its capsule intact rather than shelled out), and that changes the outcome.

The operation

Surgery for ALT is deliberately measured. Because the tumour does not spread, the aggressive margins used for high-grade sarcoma are not required, and the evidence now supports that directly. In a series of 105 patients followed for a median of 5.5 years, removing the tumour with the involved envelope of tissue (but preserving uninvolved muscle and structures) controlled the tumour as well as radical wide resection, and considerably better than simply shelling it out. Radiotherapy added nothing measurable.

Even a microscopically incomplete margin is not the failure it sounds. In a separate series of 54 patients, recurrence rates after complete and microscopically incomplete removal were statistically indistinguishable: about one in five over the years of follow-up either way. A positive margin on the pathology report is a reason for careful follow-up, not automatically for more surgery.

And for selected patients (typically where the operation would cost real function), not operating at all is an emerging option. In a recent series, 36 patients were followed with scans instead of surgery for a median of about two years: most tumours grew slowly, none spread, and none of the patients died of the disease. That experience is small and short, so it is an option to discuss at a specialist centre rather than a standard, but it reflects something true about this tumour: the danger is not the months, it is the years.

Follow-up: an honest account

Follow-up after treatment of an ALT matters more than it does for most low-grade tumours, and it is worth being straightforward about what is known and what is not.

What follow-up is for. Two things. First, local regrowth, which occurred in roughly 10–20% of patients across the series above, and is usually managed with further surgery. Second, and more importantly, dedifferentiation: a small minority of these tumours return transformed into a high-grade sarcoma. Across recent series that happened in about 4–8% of patients, and in roughly one in five of the recurrences. Catching that change early is the entire purpose of surveillance.

What the evidence says about timing. Three findings shape the plan:

1. Recurrences are late. Median time to regrowth in one series was 31.8 months (nearly three years), and the chance of remaining recurrence-free kept falling between five and ten years (88.6% at five years, 75.6% at ten). A follow-up plan that stops at two years misses much of the risk.
2. More scanning is not automatically better. The one study to examine surveillance intensity directly (in abdominal and retroperitoneal sarcoma) found that more intensive imaging schedules did not improve survival.
3. Scans over-call. When MRI suggested dedifferentiation in the surveillance series, it was confirmed on biopsy less than half the time. An alarming scan is a reason for a biopsy, not for panic.

What this means in practice. No trial has established the ideal interval between scans, and any clinic that presents its schedule as settled science is overstating the evidence. What is defensible, and what this practice does, is to commit to the things the evidence does support: follow-up measured in years, not months, typically with periodic MRI of the site; a lower threshold for imaging in tumours with higher-risk features, such as those that have recurred before; and a standing instruction that matters more than any schedule: a new lump, new growth or new pain in the area between appointments should be reported promptly rather than saved for the next visit. Most recurrences will declare themselves to the patient before a calendar finds them.

Dedifferentiated liposarcoma: the serious one

Dedifferentiation means part of a low-grade fatty tumour has transformed into a high-grade sarcoma. It can be present at the outset (typically in a longstanding abdominal tumour) or appear in a recurrence years after an ALT was removed. Unlike everything above it on this page, dedifferentiated liposarcoma can spread, and it is treated as a serious cancer from the moment it is diagnosed.

Care is led by a specialist sarcoma multidisciplinary team. The central treatment is surgery: in a population analysis of nearly 4,000 patients, surgical removal was associated with a large survival advantage, with radiotherapy adding benefit in appropriate cases. Chemotherapy has a limited role, considered case by case.

The outlook is sobering but not uniform. In that analysis, median survival was around four and a half years, with about half of patients alive at five years, and the spread around that number was wide. Tumours in the limbs did meaningfully better than the large tumours of the abdomen and retroperitoneum, and smaller tumours did better than larger ones. These were also, on average, very large tumours (the median was 14.5 cm), which is a reminder of what late diagnosis looks like in this disease, and why the ladder on this page is worth taking seriously at its bottom rungs.

Myxoid liposarcoma: the different one

Myxoid liposarcoma is the second most common liposarcoma, and everything about it argues for treating it as its own disease rather than a rung on the lipoma ladder.

It occurs in younger adults (the median age in a large treated series was 44, against the sixties typical of the MDM2 family), most often deep in the thigh. It is defined by its own genetic fusion, present in about 96% of cases, which makes the diagnosis testable in the same way MDM2 testing settles an ALT.

Two behaviours shape its treatment:

It is unusually sensitive to radiotherapy. Radiotherapy alongside surgery is used in most patients (in a series of 186, about 87% received it), and the sensitivity is reliable enough that clinical trials have tested, with encouraging early-phase results, whether the standard radiation dose can be reduced. The payoff for the patient is local control that most sarcomas cannot match: in that series, the tumour regrew where it started in only 1.6% of patients. Chemotherapy, to which it is also sensitive, is considered in higher-risk cases.

When it spreads, it spreads strangely. Most sarcomas metastasise to the lungs. Myxoid liposarcoma more often goes to soft tissue and bone: in that series, of the sites of spread, about 43% were soft tissue and 18% bone, against 23% lung. Follow-up is therefore not just a chest scan: the surveillance has to look where this tumour actually goes. Spread occurred in 17% of patients overall, and (the familiar lesson of this whole page) kept accruing late, roughly doubling between five and ten years. Cancer-specific survival was 96% at five years and 80% at ten.

For a younger patient facing this diagnosis, the honest summary is: a genuinely malignant tumour, excellent control at the primary site with modern treatment, and a long follow-up designed around its unusual habits.

Pleomorphic liposarcoma: the rare aggressive one

The rarest member of the family (fewer than 15% of liposarcomas), and the most aggressive. It behaves like any high-grade sarcoma: in a modern surgical series the tumour was controlled where it started in almost every patient, but about one in three developed distant spread within five years, which is the risk that dominates decision-making.

Surgery is the centre of treatment (in population data, not having surgery was independently associated with worse survival), with radiotherapy commonly added and chemotherapy considered case by case. Five-year survival was 54% in national registry data and 75% in a recent specialist-centre surgical series; larger tumours did consistently worse in both. It is, unambiguously, sarcoma-team territory.

What this means for you

• A small, soft, stable lump under the skin is almost always a lipoma, and a confidently diagnosed lipoma needs no treatment.
• Big, deep, or growing fatty lumps need imaging and a properly tested biopsy before removal, not because they are usually sarcoma, but because operating on the wrong assumption roughly triples the recurrence rate.
• An ALT diagnosis is not a cancer diagnosis in the ordinary sense. It does not spread. It is removed in a planned, function-preserving way, and in selected cases it can be watched instead.
• Follow-up is long because the risks are late. The schedule is individualised; the commitment to years of review is not.
• The liposarcomas are three largely separate diseases, and their treatment differs substantially: planned excision alone for ALT, radiotherapy plus surgery for myxoid, sarcoma-team care with surgery at the centre for dedifferentiated and pleomorphic. The exact name, confirmed by genetic testing, is what makes the right plan possible.
• A lipoma does not turn into liposarcoma. The only transformation in this family is an ALT becoming dedifferentiated, which is what follow-up exists to catch.

The route into assessment is the same as for any soft tissue lump (set out in tests and diagnosis), and the principle that a suspicious lump should be diagnosed before it is removed is covered in why a lump is best diagnosed before it’s removed. If you have a fatty lump with any of the features above, a referral for imaging before any surgery is the single most useful step.